Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2014

View Archived Issues

First-in-class BRD2/3/4 inhibitor OTX-015, a potential broad-spectrum anticancer drug

Novel biomarker described for Alzheimer's disease

Ono and Gilead to collaborate on global development of BTK inhibitor

First-in-class P2X3 receptor AF-219 evaluated in refractory cough

An2-conjugated anti-HER2 MAb and MAb-drug conjugates designed to cross BBB

Dr. Reddy's completes acquisition of Habitrol

Rights to anticancer drug AUY-922 revert to Vernalis

Keryx Biopharmaceuticals launches Auryxia in the U.S.

FDA grants orphan drug designation to Nuvilex treatment for pancreatic cancer

C&C Research Laboratories patent details novel STAT3 inhibitors

Merck & Co. reports CYP3A4 inhibitors to improve PK of anti-HIV drugs

Evestra reports progesterone antagonists for breast cancer

Lupin patent divulges a novel nAChR PAM

Galapagos begins first phase I study in cystic fibrosis

Approved drug CB-008 inhibits Ebola virus in vitro

Radius Health reports phase III topline results for abaloparatide-SC

INTERCEPT Blood System receives FDA approvals and meets phase II study endpoints

Travoprost approved in the E.U. for pediatric glaucoma

Chugai seeks Japanese approval of Xeloda as postoperative adjuvant chemotherapy for gastric cancer

EMA committee recommends approval of dalbavancin

E.U. marketing approval granted for Duavive for postmenopausal estrogen deficiency symptoms

Actelion files NDA for selexipag in pulmonary arterial hypertension

Medivir selects MIV-802 as drug candidate for treatment of HCV infection

Celgene receives positive CHMP opinion to extend Revlimid indication

FDA approves Soolantra for the once-daily treatment of inflammatory lesions in rosacea

Liraglutide approved in U.S. for weight loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...